Upgrade to SI Premium - Free Trial

Alnylam Pharmaceuticals (ALNY) Reiterated at Neutral by Cantor Fitzgerald Amid Exciting Pipeline Inbounds

September 30, 2026 6:58 AM
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating and $325.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments